European Journal of Clinical Pharmacology

, Volume 13, Issue 1, pp 49–53 | Cite as

Bioavailability of p-chlorophenoxyisobutyric acid (clofibrinic acid) after repeated doses of its calcium salt to humans

  • T. Taylor
  • L. F. Chasseaud
  • A. Darragh
  • D. A. O'Kelly


Plasma concentrations and bioavailability of clofibrinic acid have been estimated under conditions approaching the steady-state during a ten-day period of administration as clofibrate or as a calcium clofibrinate-carbonate combination (1:1 w/w) at a dosage interval of 12 h. Formulation — related differences in bioavailability were not significant, and the 95% confidence limits of these differences were within −2% to +8% of the mean for the reference formulation of clofibrate. The mean steadystate plasma concentrations of clofibrinic acid measured on the tenth day of dosing were 116 µg/ml±22 S.D. and 119 µg/ml±23 S.D. after administration of 885 mg as clofibrate and the calcium clofibrinate-carbonate combination respectively. The peaks of mean plasma concentrations were 70 µg/ml±15 S.D., 119 µg/ml±32 S.D. and 131 µg/ml±26 S.D. on the first, fifth and tenth day of dosing with clofibrate, and 62 µg/ml±13 S.D., 127 µg/ml±S.D. and 143 µg/ml±25 S.D. on the corresponding days of dosing with the calcium clofibrinate-carbonate combination. After the last dose on the tenth day of dosing, the mean apparent half-lives of elimination of clofibrinic acid from plasma were 24.2 h±4.4 S.D. and 25.5 h±3.2 S.D. after administration of clofibrate and the calcium clofibrinate-carbonate combination respectively.

Key words

p-Chlorophenoxyisobutyric acid clofibrate steady-state plasma concentrations bioavailability pharmacokinetics 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Thorp, J.M.: Experimental evaluation of an orally active combination of androsterone with ethyl chlorophenoxy-isobutyrate. Lancet1, 1323–1326 (1962)Google Scholar
  2. 2.
    Hunninghake, D.B., Tucker, D.R., Azarnoff, D.L.: Long-term effects of clofibrate (Atromid-S) on serum lipids in man. Circulation39, 675–683 (1969)Google Scholar
  3. 3.
    Grundy, S.M., Ahrens, E.H., Salen, G., Schreibman, P.H., Nestal, P.J.: Mechanisms of action of clofibrate on cholesterol metabolism in patients with hyperlipidaemia. J. Lipid Res.13, 513–551 (1972)Google Scholar
  4. 4.
    Beirenbaum, M.L., Fleischman, A.I., Raichelson, R.I.: Long-term human studies on the lipid effects of oral calcium. Lipids7, 202–206 (1972)Google Scholar
  5. 5.
    Taylor, T., Chasseaud, L.F.: Plasma concentrations and bioavailability ofp-chlorophenoxyisobutyric acid (clofibrinic acid) from its calcium salt in humans. J. Pharm. Sci. in pressGoogle Scholar
  6. 6.
    Barrett, A.M., Thorp, J.M.: Studies on the mode of action of clofibrate: effects on hormone-induced changes in plasma free fatty acids, cholesterol, phospholipids and total esterified fatty acids in rats and dogs. Brit. J. Pharmacol.32, 381–391 (1968)Google Scholar
  7. 7.
    Bruderlein, H., Robinson, W.T., Kraml, M., Dvornik, D.: A gas liquid chromatographic determination ofp-chlorophenoxyisobutyric acid and its comparison to an ultra-violet method. Clin. Biochem.8, 261–272 (1975)Google Scholar
  8. 8.
    Mannistő, P.T., Tuomisto, J., Jounela, A., Penttila, O.: Pharmacokinetics of clofibrate and chlorophenoxyisobutyric acid. I. Crossover studies on human volunteers. Acta Pharmacol. Toxicol.36, 353–365 (1975)Google Scholar
  9. 9.
    Metzler, C.: Bioavailability — a problem in equivalence. Biometrics30, 309–317 (1974)Google Scholar
  10. 10.
    Shirley, E.: The use of confidence intervals in biopharmaceutics. J. Pharm. Pharmacol.28, 312–313 (1976)Google Scholar
  11. 11.
    Crouthamel, W.G., Cenedella, R.J.: Clofibrate pharmacokinetics: effect of elevation of plasma — free fatty acids. Pharmacology13, 465–473 (1975)Google Scholar
  12. 12.
    Wagner, J.G.: Pharmacokinetics, p. 139. Michigan, J.M. Richards Laboratory, 1969Google Scholar
  13. 13.
    Houin, G., Thebault, J.J., d'Athis, Ph., Tillement, J.-P., Beaumont, J.-L.: A GLC method for estimation of chlorophenoxyisobutyric acid in plasma. Pharmacokinetics of a single oral dose of clofibrate in man. Europ. J. clin. Pharmacol.8, 433–437 (1975)Google Scholar
  14. 14.
    Sedaghat, A., Ahrens, E.H. Jr.: Lack of effect of cholestyramine on the pharmacokinetics of clofibrate in man. Europ. J. clin. Invest.5, 177–185 (1975)Google Scholar
  15. 15.
    Sedaghat, A., Nakamura, H., Ahrens, E.H. Jr.: Determination of clofibrate in biological fluids by thin layer and gas-liquid chromatography. J. Lipid Res.15, 352–355 (1974)Google Scholar
  16. 16.
    Berlin, A.: Quantitative gas chromatographic determination of clofibrinic acid in plasma. J. Pharm. Pharmacol.27, 54–55 (1975)Google Scholar
  17. 17.
    Cailleux, A., Allain, P.: Dosage des hypolipémiants dérivés de l'acide clofibrique dans le sérum par chromatographie en phase gazeuse. Thérapie31, 631–636 (1976)Google Scholar
  18. 18.
    Hartlapp, J.H., Gugler, R.: Single versus multiple dose pharmacokinetics of clofibrate. Arch. Pharmacol.293 Suppl. R 63 (1976)Google Scholar
  19. 19.
    Cailleux, A., Allain, P., Tadei, A.: Etude pharmacocinétique des hypolipémiants dérivés de l'acide clofibrique chez l'Homme aprés administration unique et répétée. Thérapie31, 637–645 (1976)Google Scholar

Copyright information

© Springer-Verlag 1978

Authors and Affiliations

  • T. Taylor
    • 1
  • L. F. Chasseaud
    • 1
  • A. Darragh
    • 2
  • D. A. O'Kelly
    • 2
  1. 1.Department of Metabolism and PharmacokineticsHuntingdon Research CentreHuntingdonEngland
  2. 2.Endocrine Pharmacology Unit, Department of PharmacologyUniversity College DublinEire

Personalised recommendations